GSK and RB desert Pfizer
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
GlaxoSmithKline (GSK) and Reckitt Benckiser (RB) have pulled out of the race to acquire Pfizer Consumer Healthcare, with both firms separately confirming that they had ended talks with the US pharmaceuticals giant.
You may also be interested in...
Reckitt Begins CEO Search As Kapoor Departs The Company He Reshaped
Reckitt Benckiser's long-serving CEO, Rakesh Kapoor, has unexpectedly announced his intention to retire by the end of the year, with the company immediately kicking off the search for his replacement. Kapoor will be remembered for transforming RB's consumer health business, but also for a number of setbacks under his watch which have impacted results.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.